NYMC Faculty Publications

Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension

Author Type(s)

Faculty

DOI

10.1097/CRD.0000000000000035

Journal Title

Cardiology in Review

First Page

297

Last Page

305

Document Type

Article

Publication Date

1-1-2014

Department

Medicine

Second Department

Pharmacology

Keywords

Adrenergic Antagonists, Anti-Inflammatory Agents, Antidiuretic Hormone Receptor Antagonists, Antihypertensive Agents, Drug Discovery, Drugs, Investigational, Humans, Hypertension, Pulmonary, Immunosuppressive Agents, Mineralocorticoid Receptor Antagonists, Phosphodiesterase Inhibitors, Protein Kinase Inhibitors, Receptors, Epoprostenol, Serotonin Antagonists, Stem Cell Transplantation, Vascular Remodeling, Vasodilator Agents

Disciplines

Medicine and Health Sciences

Abstract

Pulmonary arterial hypertension is a progressive and debilitating disorder with an associated high morbidity and mortality rate. Significant advances in our understanding of the epidemiology, pathogenesis, and pathophysiology of pulmonary hypertension have occurred over the past several decades. This has allowed the development of new therapeutic options in this disease. Today, our selection of therapeutic modalities is broader, including calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase inhibitors, and soluble guanylate cyclase stimulators, but the disease remains fatal. This underscores the need for a continued search for novel therapies. Several potential pharmacologic agents for the treatment of pulmonary arterial hypertension are under clinical development and some promising results with these treatments have been reported. These agents include rho-kinase inhibitors, long-acting nonprostanoid prostacyclin receptor agonists, tyrosine protein kinase inhibitors, endothelial nitric oxide synthase couplers, synthetically produced vasoactive intestinal peptide, antagonists of the 5-HT2 receptors, and others. This article will review several of these promising new therapies and will discuss the current evidence regarding their potential benefit in pulmonary arterial hypertension.

Link to Full Text

Share

COinS